Specific serum biomarkers inflammation in sarcoidosis and tuberculosis

In order to study the diagnostic and prognosis role of a complex of serum biomarkers of inflammation in active sarcoidosis and tuberculosis (angiotensin-converting enzyme (ACE), adenosine deaminase (ADA), C-reactive protein (CRP), free radicals (FvR), resistance to oxidative stress (OSR), lipid profile, indicator of lipoidosis activity (PAL) according to the developed patented formula: PAL = TC/LDLxc+TGL, correlation coefficient (СС) according to the developed patented formula: CC  = FCT/ADA), a series of single-center prospective dynamic studies were conducted: 303 patients with respiratory sarcoidosis before treatment and every 2-6 months of treatment for 3 years (patients with severe diseases of the  cardiovascular system and taking angiotensin-converting enzyme inhibitor were excluded): group 1-193 patients without exacerbation of sarcoidosis (men/women 124 (65%)/69 (35%), median age 47.3, index body weight 24.9, group 2 – 51 patients with exacerbation not treated with corticosteroids (men/women 34 (66.7%)/17 (33.3%), median age 39.5, index body weight 29.2, group 3-59 patients with exacerbation treated with corticosteroids (men/women 31 (52.5%)/28 (47.4%), median age 34.7, index body weight 29.1; 273 patients before and after 2-6 months of treatment: 151 patients with sarcoidosis and 122 patients with tuberculosis. In sarcoidosis, inflammation was characterized by increased ACE, ADA, normal CRP, dyslipidemia with decreased PAL.In tuberculosis- increased ADA, CRP, normal ACE, dyslipidemia and lowel PAL than in sarcoidosis. In sarcoidosis, CC (ACE / ADA ratio) reflects inflammatory activity with a sensitivity of 85%, specificity of 78.8%, efficiency of 80%. The complex of ACE, ADA, CC, CRP, PAL, FvR, OSR is an effective tool for monitoring granulomatous and endogenous systemic inflammation in sarcoidosis and tuberculosis.

1. Власов Т.Д., Нестерович И.И., Шиманьски Д.А. Эндотелиальная дисфункция: от частного к общему. Возврат к «старой парадигме»? // Регионарное кровообращение и микроциркуляция. – 2019. – Т. 18. –№ 2. – С. 19-27. https://doi.org/10.24884/1682-6655-2019-18-2-19-27.

2. Гармаш Ю.Ю., Новикова Л.Н., Рыжов А.М. Способ диагностики обострения саркоидоза // Патент на изобретение 2795365. С. 2-03.05. 2023. Заявка № 2023103036 от 10.02.2023.

3. Гармаш Ю.Ю., Новикова Л.Н., Рыжов А.М. Способ диагностики эндогенного воспаления у больных саркоидозом по показателю активности липоидоза // Патент на изобретение 2731887. С.1- 09. 09. 2020. Заявка № 2020101292 от 15.01.2020.

4. Каде А.Х., Занин С.А., Губарева Е.А., Туровая А.Ю., Богданова Ю.А., Апсалямова С.О., Мерзлякова С.Н. Физиологические функции сосудистого эндотелия // Фундаментальные исследования. – 2011. – № 11-3. – С. 611-617. [Электронный ресурс]. URL: https://fundamental-research.ru/ru/article/view?id=29285. (Дата обращения 01.09.2023).

5. Новиков В.Е., Левченкова О.С., Пожилова Е.В. Роль активных форм кислорода в физиологии и патологии клетки и их фармакологическая регуляция // Обзоры по клинической фармакологии и лекарственной терапии. – 2014. – Т. 12. – № 4. – С. 13-21.

6. Степанова Т.В., Иванов А.Н., Попыхова Э.Б., Лагутина Д.Д. Молекулярные маркеры эндотелиальной дисфункции // Современные проблемы науки и образования. – 2019. – № 1. [Электронный ресурс]. URL: https://science-education.ru/ru/article/view?id=28530. (Дата обращения 01.09.2023).

7. Туберкулез у взрослых. Клинические рекомендации. – 2022. [Электронный ресурс]. URL: https://cr.minzdrav.gov.ru/recomend/16. (Дата обращения 01.09.2023).

8. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Баранова О.П., Борисов С.Е. и др. Саркоидоз: федеральные клинические рекомендации по диагностике и лечению // Пульмонология. – 2022. –Т. 32. – № 6. – С. 806-833.

9. Юпатов Е.Ю., Курманбаев Т.Е., Тимошкова Ю.Л. Современное понимание функции и дисфункции эндотелия сосудов. Обзор литературы // РМЖ. – 2022. – № 3. – С. 20-23.

10. Albera C., Mabritto I., Ghio P., Solidoro P., Marchetti L., Pozzi E. Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis // Sarcoidosis. – 1993. – Vol. 10. – N. 1. –P. 18-25 PMID: 7907809.

11. Arafat SM, Adhikari MK, Ananna MA, Bahar MH, Azad AK. Value of serum adenosine deaminase (ADA) in distinguishing between tuberculous and nontuberculous lymphadenopathies // Mymensingh Med. J. – 2021. – Vol. 30. – N. 3. – P. 704-709. PMID: 34226459.

12. Baba Y., Kubo T., Yamanaka S., et al. Reconsideration of the cut-off value of angiotensin-converting enzyme for screening of sarcoidosis in Japanese patients // J. Cardiol. – 2019. – Vol. 74. – N. 6. – P. 507–511. doi:10.1016/j.jjcc.2019.05.007.

13. Bargagli E., Rosi E., Pistolesi M., Lavorini F., Voltolini L., Rottoli P. Increased risk of atherosclerosis in patients with sarcoidosis // Pathobiology. –2017. – Vol. 84. – N. 5. – P. 258–263. doi: 10.1159/000477736.

14. Brice E.A., Friedlander W., Bateman E.D., Kirsch B.E. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD // Chest. – 1995. – Vol. 107. – P. 706–710. doi: 10.1378/chest.107.3.706.

15. Carleo A., Bennett D., Rottoli P. Biomarkers in sarcoidosis: The contribution of system biology // Curr. Opin. Pulm. Med. – 2016. – Vol. 22. – P.509–514. doi: 10.1097/MCP.0000000000000306.

16. Duan J., Xu Y., Zhu H., Zhang H., Sun S., Sun H., Wang W., Xie S. Relationship between CT activity score with lung function and the serum angiotensin converting enzyme in pulmonary sarcoidosis on chest HRCT // Medicine. – 2018. Vol. 97. – e12205. doi: 10.1097/MD.0000000000012205.

17. Gao L., Wang W., Zhang Y., Hu X., An J., Li Y., Chen M., Shen Y. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study // Ther. Adv. Respir. Dis. – 2023. – Vol. 17. – 17534666231155747. doi: 10.1177/17534666231155747.

18. Ghafouri-Fard S., Noroozi R., Omrani M.D., Branicki W., Pośpiech E., Sayad A., Pyrc K., Łabaj P., Vafaee R., Taheri M. et al. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection // Vasc. Pharmacol. – 2020. Vol. 130. – 106680. doi:10.1016/j.vph.2020.106680.

19. Gundlach E., Hoffmann M.M., Prasse A., Heinzelmann S., Ness T. Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis // PLoS ONE. – 2016. – Vol. 11. – e0147258. doi: 10.1371/journal.pone.0147258.

20. Gungor S., Ozseker F., Yalcinsoy M., Akkaya E., Can G., Eroglu H., Genc N.S. Conventional markers in determination of activity of sarcoidosis // Int. Immunopharmacol. – 2015. – Vol. 25. – N. 1. – P. 174-179. doi: 10.1016/j.intimp.2015.01.015.

21. Hu X., Zou L., Wang S., Zeng T., Li P., Shen Y., Chen L. Performance of serum angiotensin-converting enzyme in diagnosing sarcoidosis and predicting the active status of sarcoidosis: a meta-analysis // Biomolecules. – 2022. – Vol. 12. – N. 10. – 1400. doi: 10.3390/biom12101400.

22. Ivanišević J., Kotur-Stevuljević J., Stefanović A., Jelić-Ivanović Z., Spasić S., Videnović-Ivanov J., Vučinić-Mihailović V., Ilić J. Dyslipidemia and oxidative stress in sarcoidosis patients // Clin. Biochem. – 2012. – Vol. 45. – N. 9. – P. 677-682. doi: 10.1016/j.clinbiochem.2012.03.009.

23. El Jahiri Y., Chellak S., Garcia C., Ceppa F., Burnat P. The usefulness of adenosine deaminase determination in biological fluids for tuberculosis diagnosis // Ann. Biol. Clin. (Paris). – 2006. – Vol. 64. – N. 2. – P. 117-124.

24. Kraaijvanger R., Janssen Bonas M., Vorselaars A. D. M., Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects // Front. Immunol. – 2020. – Vol. 11. – P. 1443. doi:10.3389/fimmu.2020.01443.

25. Krasowski M.D., Savage J., Ehlers A., Maakestad J., Schmidt G.A., La’ulu S.et al. Ordering of the serum angiotensin-converting enzyme test in patients receiving angiotensin-converting enzyme inhibitor therapy: an avoidable but common error // Chest. – 2015. – Vol. 148. – N. 6. – P. 1447-1453.

26. Landi C., Bargagli E., Carleo A. et al: A functional proteomics approach to the comprehension of sarcoidosis // J. Proteomics. – 2015. – Vol. 128. – P. 375-387.

27. Lastra C. A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications // Biochemical Society Transactions. – 2007. – Vol. 35. – N. 5. – P. 1156 – 1160.

28. Liu M., Wang T., Zhou Y., Zhao Y., Zhang Y., Li J. Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management // J. Transl. Intern. Med. – 2020. – Vol. 8. – P. 9–19. doi:10.2478/jtim-2020-0003.

29. Lopes M.C., Amadeu T.P., Ribeiro-Alves M., da Costa C.H., Rodrigues L.S., Bessa E.J.C., Bruno L.P., Lopes A.J., Rufino R. Identification of active sarcoidosis using chitotriosidase and angiotensin-converting enzyme // Lung. – 2019. – Vol. 197. – P. 295–302. doi:10.1007/s00408-019-00219-2.

30. Miura K, Takahashi K, Fukuchi Y. Role of biochemical markers in sarcoidosis // Nihon Rinsho. – 2002. – Vol. 60. – N. 9. – P. 1741-1746. Japanese.

31. Mochizuki I., Kubo K., Hond T. Widespread heavy damage of capillary endothelial cells in the pathogenesis of sarcoidosis – evidence by monoclonal von Willebrand factor immunohistochemistry in the bronchus and lung of patients with sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. – 2014. – Vol. 31. – P. 182-190.

32. Mochizuki I, Kubo K, Honda T: Relationship between mitochondria and the development of specific lipid droplets in capillary endothelial cells of the respiratory tract in patients with sarcoidosis // Mitochondrion. – 2011. – Vol. 11. – P. 601-606.

33. Popević S., Šumarac Z., Jovanović D., Babić D., Stjepanović M., Jovičić S., Šobić-Šaranović D., Filipović S., Gvozdenović B., Omčikus M. et al. Verifying sarcoidosis activity: chitotriosidase versus ACE in sarcoidosis—a case-control study // J. Med. Biochem. – 2016. – Vol. 35. – P. 390–400. doi:10.1515/jomb-2016-0017.

34. Ramos-Casals M., Retamozo S., Siso-Almirall A., Perez-Alvarez R., Pallares L., Brito-Zeron P. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis // Expert Rev. Clin. Immunol. – 2019. – Vol. 15. – P. 391–405. doi:10.1080/1744666X.2019.1568240.

35. Romer F.K. Angiotensin-converting enzyme activity in sarcoidosis and other disorders // Sarcoidosis. – 1985. – Vol. 2. – P. 25–34.

36. Rosen Y. Pathology of Sarcoidosis // Semin. Respir. Crit. Care Med. – 2007. – Vol. 28. – P. 036–052. doi: 10.1055/s-2007-970332.

37. Springer-Wanner C., Brauns T. Okuläre Sarkoidose // Zeitschrift Rheumatol. – 2017. – Vol. 76. – P. 391–397. doi: 10.1007/s00393-017-0303-7.

38. Stoian I., Oros A., Moldoveanu E. Apoptosis and free radicals // Biochem. Mol. Med. – 1996. - Vol. 59. – N. 2. – P. 93 – 97.

39. Studdy P.R., Bird R. Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice // Ann. Clin. Biochem. – 1989. – Vol. 26. – N. 1. – P. 13–18. doi: 10.1177/000456328902600102.

40. Wang W., Ma Y., Zhang Y., Lin J.W., Nong Y., Zhang X., Jia Y. Diagnostic and staging value of serum angiotensin-converting enzyme in sarcoidosis // Comput. Math. Methods Med. – 2022. Published online 2022 Feb 22. doi:10.1155/2022/4657502.

41. Wetzel E, Müller-Quernheim J, Lorenz J. Die Serum-Adenosindesaminase als Aktivitätsparameter der Sarkoidose // Pneumologie. – 1999. – Vol. 53. – N. 7. –P. 323-328.

42. Yang H., Mo T., Nie W., Li B. Angiotensin converting enzyme I/D polymorphism and sarcoidosis risk // Sarcoidosis Vasc. Diffus. lung Dis. Off. J. WASOG. – 2016. – Vol. 32. – P. 284–288.